Nanobiotix Reports Exciting Preclinical Results Using Its nanoXray Therapeutics Technology to Destroy Tumors

Intratumoral injection of NBTXR3 nanoparticles activated via standard radiation
therapy led to complete tumor regression compared to zero tumor regression in
mice treated with xray only

Study conducted at Institut Gustave Roussy under principal investigator and
radiation oncologist/researcher Jean Bouris, M.D., Ph.D.
PARIS--(Business Wire)--
Nanobiotix, an emerging nanomedicine company, announced today exciting
preclinical results using its patented nanoXraytherapeutics platform to fight
tumors. The preclinical study, performed at Institut Gustave Roussy, one of
Europe`s leading cancer treatment centers, showed that an intratumoral injection
of NBTXR3 nanoparticles and activated via standard radiation therapy led to
complete tumor regression in mice at 60 days, compared to zero tumor regression
in mice treated with xray only or NBTXR3 only. The study was led by principal
investigator Jean Bourhis, M.D., Ph.D., a prominent radiation oncologist and
researcher at Institut Gustave Roussy.

Nanobiotix is using technology that it calls `nanoXraytherapeutics` to resolve
radiation therapy`s biggest drawback: destruction of healthy tissue and its
subsequent deleterious side effects when a high dose of xray is necessary. The
Company believes that nanoXraytherapeutics offer a dramatic innovation in cancer
therapy, based on a technology that is designed to allow destruction of cancer
cells only-a new treatment weapon that could be used alone, or in concert with
existing anticancer protocols: chemotherapy, surgery, and immunotherapy. Because
NBTXR3 is comprised of crystalline nanoparticles, it does not have deleterious
effects on healthy cells, unlike chemotherapy or other systemic anticancer
agents.

"Our nanotechnology is designed to allow for the precise destruction of cancer
cells via the controlled application of an outside-the-body energy source-in
this case, an xray. We are extremely excited by these preclinical results, which
demonstrate the novel therapeutic effect of nanoparticles on human tumor
models," said Laurent Lévy, Ph.D., President and CEO of Nanobiotix and
Co-President of the French Technology Platform on Nanotechnology (FTPN).

"It is very important to note that after 120 days of this study, 90 percent of
the mice treated with NBTXR3 nanoparticles activated by radiotherapy were still
alive, whereas all of the mice in the other two groups had to be sacrificed
after 60 days due to tumor progression," added Elsa Borghi, M.D., Chief Medical
Officer for Nanobiotix.

One in four deaths in the United States is from cancer, making it the
second-leading cause of death after heart attack. Radiation therapy-also called
radiotherapy, xray, or irradiation-is typically used to kill cancer cells and
shrink tumors. Radiation therapy injures or destroys cells in the area being
treated by damaging their genetic material, making it impossible for these cells
to continue to grow and divide. The goal of radiation therapy is to damage as
many cancer cells as possible, while limiting harm to nearby healthy tissue.
About half of all cancer patients receive some type of radiation therapy, which
may be used alone or in combination with other cancer treatments, such as
chemotherapy or surgery. Radiation therapy may be used to treat almost every
type of solid tumor.

About the NBTXR3 Preclinical Study

Through experiments on resistant and radiosensitive tumor models, NBTXR3
activated by xray has shown its strong ability to reduce the clonogenic activity
of cancer cells. In vivo models have demonstrated the same type of improvement,
up to tumor elimination, when radiotherapy alone could show only five-day tumor
growth delay. In several models including an HCT116 colon cancer tumor and an
HT1080 fibrosarcoma tumor, NBTXR3 has strongly impaired tumor growth and
improved Overall Survival (OS). The study showed a statistically significant
tumor regression and a prolongation of survival in NBTXR3-treated mice when
irradiated both with one dose of 8 Gy or two doses of 4 Gy. This is an important
parameter since radiation therapy is delivered in fractions to cancer patients.

Similar results were also obtained with Swiss nude mice bearing sarcoma tumors,
in spite of the fact that these are known to be resistant to radiotherapy. Other
studies in non-epithelial cancer models demonstrated comparable survival
improvements as well. Compatibility with different energy sources has also been
demonstrated, proving that NBTXR3 could be easily used with the different
radiotherapy equipment presently on the market.

ABOUT NANOBIOTIX

Nanobiotix is an emerging nanomedicine company combining dramatic advances in
nanotechnology and molecular biology to develop nanoXray- a technology platform
that is expected to be turned `on` and `off` outside the body to selectively
treat a variety of cancers safely and noninvasively. Use of nanoXray is intended
to resolve radiation therapy`s biggest drawback: destruction of healthy tissue
and its subsequent deleterious side effects when a high dose of xray is
necessary. The core of a nanoXray nanoparticle is an inactive and inert
substance-not a drug-that can be activated to locally (intratumor) increase the
dose of xray, which is then expected to lead to higher efficiency. After
nanoXray nanoparticles accumulate in the target tissues, a standard xray is
applied that is intended to generate a local therapeutic effect, designed to
destroy only the targeted tumor cells. This mechanism suggests total control of
the intended therapeutic effect.

Ronald Trahan Associates Inc.
Ronald Trahan, APR, 508-359-4005, x108

Copyright Business Wire 2009